期刊: ANNALS OF HEMATOLOGY, 2022; 101 (2)
Persistent thrombocytopenia (PT) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with an increased risk of bleeding......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (10)
Relapse and refractoriness remain the major obstacles in clinical treatment of acute myeloid leukemia (AML). Efficacy of current therapeutic strategie......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (12)
To investigate the pathogenesis and the refractory/relapse mechanisms in patients with t(16;21)(p11;q22), we retrospectively analyzed the clinical dat......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (12)
Hetrombopag is the only CFDA-approved thrombopoietin (TPO) receptor agonist for severe aplastic anemia (SAA) in China. Its chemical structure has an i......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (4)
Idarubicin 12 mg/m(2) has been recommended as a standard induction therapy for acute myeloid leukemia (AML). It is unknown whether a higher dose of id......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (5)
Immune thrombocytopenia (ITP) is the most common clinical bleeding disorder with a high mortality rate and poor long-term survival quality in severe p......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (8)
Background Malignant lymphomas are one of the most common cancers worldwide and with high biologic heterogeneity, while the phosphoinositide 3 kinase ......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (3)
We started a single-arm, phase II, open-label, prospective clinical trial using steroids-ruxolitinib as the first-line therapy for intermediate- to hi......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (3)
HBB gene mutations lead to many kinds of diseases, of which, except for the two most common diseases of thalassemia and sickle cell anemia, rare kinds......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (9)
The present study aims to evaluate the characteristics and treatment outcomes of adult Langerhans cell histiocytosis (LCH) patients with thyroid invol......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (4)
Acquired aplastic anemia (AA) is an autoimmune disease characterized by hematopoietic stem and progenitor cell destruction in bone marrow. The non-cla......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (10)
Marginal zone lymphoma (MZL) is an uncommon subtype of non-Hodgkin lymphoma (NHL). Combination of rituximab and cladribine (R-2CdA) is a potential opt......
期刊: ANNALS OF HEMATOLOGY, 2022; 101 (10)
P53 prognostic cut-off values differ between studies of mantle cell lymphoma (MCL), and its immunohistochemistry (IHC) interpretation is still based o......